



JFW

Attorney Docket No.: 6544.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Persson et al.

Serial No.: 10/669,537

Group Art Unit: 1653

Filed: September 24, 2003

Examiner: To be assigned

For: Human Coagulation Factor VII Polypeptides

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:


1. Response to Notice to Comply with Sequence Rules
2. Sequence Listing
3. Copy of Notice to Comply with Sequence Rules
4. Disk Containing Sequence Listing

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Sequence  
U.S Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

on May 25, 2004

Tracy Bronner  
(name of person mailing paper)

  
(signature of person mailing paper)



Attorney Docket No.: 6544.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Persson et al.

Serial No.: 10/669,537

Group Art Unit: 1653

Filed: September 24, 2003

Examiner: To be assigned

For: Human Coagulation Factor VII Polypeptides

**RESPONSE TO NOTICE COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO  
ACID SEQUENCE DISCLOSURES**

MS: Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure, a copy of which is enclosed, applicants enclose herewith the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing. The content of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labeled diskette is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. No new matter is added.

No fee is due for this submission. However, please charge any fee, should it be required, to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,



\_\_\_\_\_  
Reza Green, Reg. No. 38,475  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800


**Use the following customer number for all correspondence regarding this application.**

**23650**

PATENT TRADEMARK OFFICE



**UNITED STATES PATENT AND TRADEMARK OFFICE**



UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/669,537	09/24/2003	Egon Persson	6544.200-US

Reza Green, Esq.  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540

DOCKET (check off ✓)

ATTY: *TAB DCT 3/29/04*

**CONFIRMATION NO. 4625**

**FORMALITIES LETTER**



\*OC00000001219231\*

Date Mailed: 03/25/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*MAR 29 2004*

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450

Alexandria VA 22313-1450

---

*A copy of this notice **MUST** be returned with the reply.*

B. Habtemari

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY